Assess whether the primary endpoint will survive FDA scrutiny (0dd396)

SITUATION A CRL citing manufacturing, not efficacy put scientific-advice briefing book in front of clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / CMC and Development Pathways decision is the primary endpoint will from scientific-advice briefing book, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. The population in scientific-advice briefing book is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this CMC and Development Pathways file. 2. The population in scientific-advice briefing book is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained a CRL citing manufacturing, not efficacy before scientific-advice briefing book arrived; no new CMC and Development Pathways path. 4. Provenance on scientific-advice briefing book after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Check whether scientific-advice briefing book supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 3. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a CRL citing manufacturing, not efficacy. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a CRL citing manufacturing, not efficacy and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in scientific-advice briefing book, then the action for clinical-development physician - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Missing page in scientific-advice briefing book after a CRL citing manufacturing, not efficacy, if any - Regulatory or exam hook CMC and Development Pathways would cite